

USP and the U.S. government: Advancing supply chain security



USP is an independent, scientific organization that builds trust in the supply of safe, quality medicines worldwide. Our team works to strengthen the global supply chain so that the medicines Americans rely on are available when needed and work as expected.

150+
countries recognize
USP standards

4 billion
people around the world
rely on medicines that use
USP standards



931
Scientific Expert Volunteers
and government liaisons
form USP network


Harnessing our cross-sector convening power to solve pressing challenges by:

- ▶ Tackling supply chain shortages in high-impact consortia, including:
 - Drug Shortage Task Force
 - Duke-Margolis ReVAMP Drug Supply Chain Consortium
 - BARDA BioMaP Consortium
 - Alliance for Building Better Medicine
 - End Drug Shortages Alliance
- ▶ Advancing the application of scientific knowledge through the **Nitrosamines Exchange** and the **Continuous Manufacturing Knowledge Center**.


Our capabilities and expertise



**Predictive supply
chain mapping and
risk mitigation, from
precursors to
finished products**




**Standardized quality
processes for
biomanufacturing and
platform technologies**



**Validated analytical
methods and product
quality testing**



**Workforce
modernization for
Pharma 4.0**



**Scale up of advanced
manufacturing to support
onshoring, reshoring, and
distributed manufacturing**

Our 25+ years of work with federal agencies

Department of Defense (DoD): Establishing quality methods for advanced manufacturing of active pharmaceutical ingredients for the development of medical countermeasures.

Advanced Research Projects Agency for Health (ARPA-H): Accelerate biomanufacturing innovations and distributed manufacturing through quality systems and process control strategy development, particularly for advanced manufacturing technologies.

Administration for Strategic Preparedness and Response (ASPR): Examining the upstream pharmaceutical supply chain and providing recommendations to strengthen its resiliency.

Biomedical Advanced Research and Development Authority (BARDA): Leveraging our expertise to advance the safe development and production of medical countermeasures through the BioMaP Consortium to help prepare for and respond to public health emergencies.

Food and Drug Administration (FDA): Developing ways to enhance interchangeable biosimilar product development and regulatory science, specifically through use of the Multi-Attribute Method (MAM), helping to lower barriers to adoption and enable wider use of MAM.



Learn more about working with us by visiting usp.org/federal-government-solutions